Učitavanje...
Multiple Source Biosimilar Insulin, What’s a Provider to Do?
In the United States the FDA designates generic products that are bioequivalent as AB substitutable (FDA rating signifying the approved application contains adequate scientific evidence establishing through in vivo and/or in vitro studies the bioequivalence of the product to a selected reference pro...
Spremljeno u:
| Izdano u: | J Diabetes Sci Technol |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4454116/ https://ncbi.nlm.nih.gov/pubmed/24876532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296813511748 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|